MAPK3 and cancer: Early evidence of the involvement of DUSP4 in cancer was provided by Yip and colleagues, who showed that PDAC cells expressing oncogenic KRAS upregulates the expression of DUSP4 to counteract ERK1/2 pathway activation [96].